Maintenance of skeletal muscle quantity and quality is crucial for healthy aging, and is facilitated by a remarkable tissue plasticity. Muscle-resident stem cells (MuSC) provide an important contribution to this plasticity by differentiation and subsequent fusion with the myofiber – a process called myonuclear accretion. The progression of this process is characterised by distinct MuSC metabolic requirements, and seems to depend on the myofiber metabolic state. We therefore anticipated a role of metabolism – and specifically, the metabolic regulator AMPKalpha2 – in myofiber to the MuSC signalling, directing MuSC fate towards myonuclear accretion. A better understanding of the process of myonuclear accretion and its regulation will be important to better understand disease aetiology and pathophysiology and will contribute to a better treatment (e.g. by AMPK activators) of patients with patient with (metabolic) diseases leading to muscle pathology that may be caused by impaired myonuclear accretion. The overall objectives of the project constitute a ‘proof of principle’, ‘target identification’, and ‘target validation’.